• Strong Balance Sheet with $203M capital raise
• Robust supply chain strategy for isotopes and product manufacturing
• Advancing multiple registrational clinical trials in prostate cancer and neuroendocrine tumors
• Granted 3 Fast Track Designations by US FDA

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, presented an update on its business at the Annual General Meeting. The company reported a strong balance sheet following a $203 million capital raise, which will fund the development of its pipeline. Clarity highlighted its robust supply chain strategy, with isotopes and products manufactured in the US to avoid tariffs and geopolitical instability. The company is advancing multiple registrational clinical trials, including the CLARIFY and AMPLIFY Phase III trials evaluating its 64Cu-SAR-bisPSMA diagnostic agent in prostate cancer, the SECuRE Phase I/IIa trial of 64Cu/67Cu-SAR-bisPSMA theranostic in metastatic castrate-resistant prostate cancer, and the DISCO Phase II trial of 64Cu-SARTATE in neuroendocrine tumors. Clarity also discussed its discovery pipeline, including 64/67Cu-SAR-bisFAP and 64/67Cu-SAR-Trastuzumab. The company noted that its team has grown from 55 employees in November 2024 to 75 team members today, with 57% based in Australia and 43% in the US. Clarity also highlighted that 70.7% of the team, one third of the Board, and a third of the Senior Executive Team are female.

Clarity Pharmaceuticals reported a strong balance sheet following a $203 million capital raise, which will fund the development of its pipeline. The company is advancing multiple registrational clinical trials and expects to submit applications to the US FDA for the approval of 64Cu-SAR-bisPSMA in pre-prostatectomy and biochemical recurrence of prostate cancer indications.

Clarity Pharmaceuticals is focused on advancing its clinical development pipeline, including registrational trials for its 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic agents in prostate cancer, as well as its 64Cu-SARTATE diagnostic agent in neuroendocrine tumors. The company is also progressing its discovery pipeline, including 64/67Cu-SAR-bisFAP and 64/67Cu-SAR-Trastuzumab.